cholecystokinin

Gastrin I, human (Gastrin I (human)) is an endogenous peptide produced in the stomach that increases pepsinogen and acid secretion via the CCK2 receptor in the rat.

PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.

XL413 hydrochloride (BMS-863233 Hydrochloride) is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC 50 of 3.4 nM. XL413 hydrochloride also exhibits potent effect with IC 50 s of 215, 42 nM on CK2, PIM1, respectively, and an EC 50 of 118 nM on pMCM.

Itriglumide (CR-2945) is a cholecystokinin (CCK)-2 receptor antagonist with antisecretory and antiulcerogenic properties.

XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induct

A-65186 is an A-type glutamatergic cholecystokinin (CCK) antagonist used to study inflammation and gastrointestinal tract injury.

GV150013 is an antagonist of cholecystokinin-2 (CCK2) receptor.

Sincalide ammonium (CCK-8 ammonium) is a potent analog of the amino acid peptide hormone cholecystokinin (CCK), an active fragment that retains much of the biological activity of CCK.Sincalide ammonium promotes bile secretion, causes gallbladder contractions and relaxes the sphincter of Oddi, thereby facilitating bile drainage into the duodenum. Sincalide ammonium promotes bile secretion, contraction of the gallbladder and relaxation of the sphincter of Oddi, thereby facilitating the drainage of bile into the duodenum.Sincalide ammonium can be injected to promote gallbladder contraction, and is commonly used as an adjunct in the diagnosis of gallbladder and pancreatic diseases and in cholecystography.

Proglumide (Binoside) is a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.

GI 181771 is an agonist of the cholecystokinin 1 receptor. GI 181771 can be used in studies about obesity.

Pranazepide (FK 480) is a small molecule cholecystokinin receptor antagonist used to study digestive disorders and pancreatitis.

Lintitript (SR 27897) is a selective CCK1 antagonist with an EC50 of 6 nM for CCK1 and 200 nM for CCK2, and a Ki value of 0.2 nM for CCK1.

Pentagastrin (ICI-50123) is a synthetic polypeptide that mimics the effects of gastrin when administered parenterally, influencing the secretion and synthesis of salivary proteins.

Lorglumide sodium salt (CR-1409 sodium salt) is an antagonist of cholecystokinin receptors (CCK).

Cholecystokinin (26-33) free acid, a part of cholecystokinin (CCK), is a highly selective ligand for CCKB-type receptors found in the vertebrate CNS and induces a mild taste aversion conditioned reflex in rats.

Gastrin I (human) acetate (Gastrin-17 acetate) is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.

L-365260 is an orally available, selective and potent nonpeptide gastrin and cerebral cholecystokinin receptor (CCK-B) antagonist.L-365260 inhibits CCK-8S-induced increase in [Ca2+]i, blocks stress-induced hypersensitivity in viscera, and blocks the anti-exploratory effect of CCK-4.L-365260 has been used in the study of neurological Ojibwa and endocrine diseases.

Loxiglumide (CR-1505) is an antagonist of cholecystokinin (CCK-1) receptor.

Nastorazepide (Z-360) is a selective, orally available antagonist of the gastrin cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity.

CCK Octapeptide, non-sulfated acetate is a synthetic desulfated peptide of cholecystokinin.

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate ([D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P acetate (96736-12-8 free base)) is a broad spectrum neuropeptide inverse agonist and antagonist. Potent full inverse agonist for the ghrelin receptor (EC50 = 5.2 nM); diminishes constitutive ghrelin receptor signaling. Also antagonist at tachykinin, bradykinin, CCK and bombesin receptors. Induces apoptosis and inhibits cancer cell growth in vitro.

WAY-620645 is a CCK antagonist with antitumor and analgesic activities.

(Iso)-FK-480 is a novel orally available cholecystokinin A (CCK-A) antagonist for investigational treatment of chronic pancreatitis.

GV-150013X ((S)-1-(1-(adamantan-1-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-3-phenylurea) is a potent CCKB antiagonist, pKi= 9.02.

N-Cbz-DL-tryptophan is a cholecystokinin receptor antagonist, abolished the response of the isolated heart to CCK-8.

Spiroglumide, a CCKB-gastrin antagonist that inhibits dose-dependent pentagastrin-induced acid hypersecretion with an ID50 of 20.1 (8.67-46.4) mg kg, could be used to explore the physiological role of gastrin in the regulation of human gastric acid secretion.

Ceruletide Ammonium Salt is a decapeptide, originating from the skin of tropical frogs, which is a potent cholecystokinin receptor agonist and a safe and effective cholecystokinin receptor agonist with direct spasmodic effects on the gallbladder muscle and bile ducts. Ceruletide Ammonium Salt has sedative activity and has been used in the study of chronic schizophrenia.Ceruletide Ammonium Salt is a decapeptide, originating from the skin of tropical frogs.

Mini Gastrin I, human acetate is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide.

Ceruletide Ammonium acetate (FI-6934 Ammonium acetate) is a cholecystokinin (CCK) receptor agonist. Ceruletide Ammonium acetate is a safe and effective cholecystokinetic agent and small bowel and exocrine pancreatic stimulant.

CCK-A receptor inhibitor 1 is a potent cholecystokinin A (CCK-A) receptor inhibitor (IC50: 340 nM) and can be used to study digestive system-related diseases.

Gastrin CCK antagonist 1 is a potent gastrin CCK antagonist for the study of metabolic system-related diseases.